Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) is an inflammatory disorder consisting of (1) subacute clinical brainstem signs and symptoms, (2) characteristic punctate and curvilinear perivascular peppercorn-like gadolinium enhancement of the pons, brachium pontis, and cerebellum in MRI, (3) dense perivascular CD4 + T cell predominant inflammatory cell infiltrates in biopsy, and (4) clinical and radiologic response to steroids in the absence of alternative diagnosis.
MR imaging showed small infratentorial lesions in the pons, bilateral middle cerebral peduncles and medulla oblongata with associated strong "salt and pepper" like Gadolinium uptake, and linear appearance suggestive of a perivascular localization as well as an upper cervical spinal cord lesion (figure, A-E). Prominent extrapontine manifestations developed during the course of the disease (figure, F-H). Brain biopsy (right temporal lesion, figure, I-N) showed extensive perivascular, less marked vascular but also parenchymal infiltration of predominantly CD4 + T-lymphocytes and few B-lymphocytes without features of vasculitis (no destruction of the vessel wall with fibrinoid necrosis, leukocytoclasia, or fibrin thrombi). These bioptic features have been noted as a hallmark in CLIPPERS. 5 Few small necrotic lesions were evident. An extensive workup for known infectious, inflammatory, and neoplastic etiologies was negative.
From 2007 to 2011, the patient received multiple doses of IV methylprednisolone and intrathecal triamcinolone with clinical and radiologic improvement (figure, O). However, this always only led to a short-term improvement with subsequent evidence of disease activity even under continued oral steroid tapers. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Therefore, nonsteroidal disease-modifying therapy was initiated. Under azathioprine therapy, the patient experienced a significant increase in infratentorial and especially supratentorial Gadolinium-enhancing lesions. She was switched to cyclophosphamide, which at first lead to a significant radiologic improvement. However, symptoms progressed in 2009 under ongoing cyclophosphamide treatment, which was stabilized by addition of tacrolimus. After 13 cycles and a cumulative dose of 24,800 mg, cyclophosphamide therapy was discontinued in December 2009 with consecutive clinical and radiologic worsening.
During a trial of TNF-α blockers with monthly infliximab infusions in 2010, no new or enlarging brain lesions were observed
After a short phase of mycophenolate mofetil therapy and a 5-day cycle of plasmapheresis, treatment with tocilizumab was initiated in October 2011 (initially 480 mg IV monthly, then 162 mg SC weekly since 2016), under which the patient's presentation rapidly stabilized and started to continuously improve both clinically and radiologically with no further signs of relapse (observation period: 6 years, last MRI brain and clinical follow-up in September 2017). The ongoing comedication with tacrolimus was tapered down and discontinued in 2015 without any symptomatic worsening.
Discussion
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